Sanofi: positive results from Dupixent study

(CercleFinance.com) - Sanofi today announces that its pivotal phase III trial evaluating Dupixent (dupilumab) in the Treatment of teenagers (12 to 17 years old) with moderate-to-severe atopic dermatitis has met its primary endpoint and important secondary endpoints.


As part of this trial, treatment by Dupixent as a monotherapy significantly reduced the overall severity of the disease and improved skin scarring, itching and a number of health-related quality of life measures, the group explained.

Dupixent is the first and only biological agent to have achieved positive results in this category of patients. An application for regulatory approval is expected to be submitted in the US in the third quarter for patients aged 12 to 17.



Copyright (c) 2018 CercleFinance.com. All rights reserved.